Cytek Biosciences
CTKB
About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Employees: 688
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
38% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 47
2.14% more ownership
Funds ownership: 60.55% [Q1] → 62.69% (+2.14%) [Q2]
3% less funds holding
Funds holding: 161 [Q1] → 156 (-5) [Q2]
13% less capital invested
Capital invested by funds: $311M [Q1] → $270M (-$41M) [Q2]
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Financial journalist opinion
Based on 3 articles about CTKB published over the past 30 days
